advertisement

---

Lu F 8

Showing records 1 to 8 | Display all abstracts from Lu F

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Wirta DL
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

99098 Clinical Significance of Albumin- and Bilirubin-Based Biomarkers in Glaucoma: A Retrospective Case-Control Study
He C
Oxidative medicine and cellular longevity 2022; 2022: 8063651

---

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Kuwayama Y
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

99098 Clinical Significance of Albumin- and Bilirubin-Based Biomarkers in Glaucoma: A Retrospective Case-Control Study
Zhang G; Fu J
Oxidative medicine and cellular longevity 2022; 2022: 8063651

---

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Lu F; Shao H
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

99098 Clinical Significance of Albumin- and Bilirubin-Based Biomarkers in Glaucoma: A Retrospective Case-Control Study
Zhang R
Oxidative medicine and cellular longevity 2022; 2022: 8063651

---

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

99098 Clinical Significance of Albumin- and Bilirubin-Based Biomarkers in Glaucoma: A Retrospective Case-Control Study
Li A; Liu D; Li B; Chen Y; Deng B; Shuai P; Lu F
Oxidative medicine and cellular longevity 2022; 2022: 8063651

---